FDA approves much-debated Alzheimer’s drug panned by experts
3 years, 6 months ago

FDA approves much-debated Alzheimer’s drug panned by experts

Associated Press  

WASHINGTON — Government health officials on Monday approved the first new drug for Alzheimer’s disease in nearly 20 years, disregarding warnings from independent advisers that the much-debated treatment hasn’t been shown to help slow the brain-destroying disease. The Food and Drug Administration approved the drug from Biogen based on study results showing it seemed “reasonably likely” to benefit Alzheimer’s patients. Dr. Caleb Alexander, an FDA adviser who recommended against the drug’s approval, said he was “surprised and disappointed” by the decision. The FDA’s top drug regulator acknowledged that “residual uncertainties” surround the drug, but said Aduhelm’s ability to reduce harmful clumps of plaque in the brain is expected to help slow dementia. Although Biogen studied the drug in people with mild dementia or early-stage Alzheimer’s, the FDA label approved the drug for anyone with Alzheimer’s, a sweeping population given doctors have broad leeway in diagnosing the condition.

Disease Brain Patients Drug Study Fda Ability Biogen  disease  including  patients  experts  muchdebated  drug  biogen  fda  ability  alzheimers  brain  approves  panned  study

History of this topic

New Alzheimer's drug: only a few eligible for treatment
1 month, 1 week ago

New Alzheimer's drug: only a few eligible for treatment

NL Times  

It is estimated that less than one in ten people with dementia are eligible for treatment with Lecanemab or Leqembi, the slowing agent that is still allowed on the European market by the European Medicines Agency. That is why Alzheimer Nederland calls for a fast track "so that patients and their families are not unnecessarily in uncertainty for a long …

Tens of thousands to be recruited into Alzheimer’s trials after landmark drug rejected
2 months ago

Tens of thousands to be recruited into Alzheimer’s trials after landmark drug rejected

The Telegraph  

Tens of thousands of people will be recruited into Alzheimer’s trials after a landmark drug was rejected for use on the NHS. Charities said the announcement was “another frustrating setback” for people affected by Alzheimer’s disease, describing the decision as “incredibly disappointing”. Hilary Evans-Newton, the chief executive at Alzheimer’s Research UK, urged Wes Streeting to “break the deadlock we’re facing, …

Researchers investigating if drugs can be repurposed to combat dementia
2 months, 1 week ago

Researchers investigating if drugs can be repurposed to combat dementia

The Independent  

Sign up for our free Health Check email to receive exclusive analysis on the week in health Get our free Health Check email Please enter a valid email address Please enter a valid email address SIGN UP I would like to be emailed about offers, events and updates from The Independent. Prof Hooper said: “What we’re interested in – because …

Second Alzheimer’s drug expected to be blocked for NHS use
4 months ago

Second Alzheimer’s drug expected to be blocked for NHS use

The Telegraph  

A second Alzheimer’s drug is expected to be blocked for use by the NHS, The Telegraph can reveal. This week, the breakthrough drug lecanemab was declared safe by the medicines regulator but was not approved for use on the NHS by the health service’s spending watchdog. Insiders told The Telegraph that the National Institute for Health and Care Excellence, which …

What are the symptoms and treatments for Alzheimer’s – as new drug is rejected
4 months ago

What are the symptoms and treatments for Alzheimer’s – as new drug is rejected

The Independent  

Sign up to our free Living Well email for advice on living a happier, healthier and longer life Live your life healthier and happier with our free weekly Living Well newsletter Live your life healthier and happier with our free weekly Living Well newsletter SIGN UP I would like to be emailed about offers, events and updates from The Independent. …

European committee says Alzheimer’s treatment Leqembi shouldn’t get marketing approval
4 months, 4 weeks ago

European committee says Alzheimer’s treatment Leqembi shouldn’t get marketing approval

Associated Press  

Shares of Biogen slid Friday after a European regulatory committee said the Alzheimer’s treatment Leqembi should not receive marketing approval. The European Medicines Agency committee said concerns about the drug’s potential side effects outweigh the impact it has in slowing the fatal, mind-robbing disease. Japanese drugmaker Eisai developed Leqembi and is co-marketing it with Cambridge, Massachusetts-based Biogen Inc. An Eisai …

Eli Lilly Alzheimer's drug approved by US FDA
5 months, 3 weeks ago

Eli Lilly Alzheimer's drug approved by US FDA

Hindustan Times  

By Bhanvi Satija Eli Lilly Alzheimer's drug approved by US FDA July 2 - The U.S. Food and Drug Administration on Tuesday approved Eli Lilly's treatment for early Alzheimer's, making it the second therapy for slowing progression of the brain-wasting disease that will be available to U.S. patients. The approval for donanemab, to be sold under brand name Kisunla, followed …

FDA approves another Alzheimer's drug that can slow disease in its early stages
5 months, 3 weeks ago

FDA approves another Alzheimer's drug that can slow disease in its early stages

Hindustan Times  

U.S. officials have approved another Alzheimer’s drug that can modestly slow the disease, providing a new option for patients in the early stages of the incurable, memory-destroying ailment. “It’s been difficult as a dementia specialist — I diagnose my patients with Alzheimer’s and then every year I see them get worse and they progress until they die.” Both Kisunla and …

FDA approves a second Alzheimer’s drug that can modestly slow disease
5 months, 3 weeks ago

FDA approves a second Alzheimer’s drug that can modestly slow disease

Associated Press  

WASHINGTON — U.S. officials have approved another Alzheimer’s drug that can modestly slow the disease, providing a new option for patients in the early stages of the incurable, memory-destroying ailment. It’s only the second drug that’s been convincingly shown to delay cognitive decline in patients, following last year’s approval of a similar drug from Japanese drugmaker Eisai. “It’s been difficult …

An Alzheimer drug gets a boost
6 months, 1 week ago

An Alzheimer drug gets a boost

Live Mint  

Developing new medicines entails enormous risk and perseverance. Take Eli Lilly’s Alzheimer’s disease treatment donanemab, which a Food and Drug Administration advisory committee on Monday unanimously recommended for approval. After one pivotal trial in 2016 disappointed, some dismissed Lilly’s strategy of targeting amyloid plaque in the brain—a signature of the disease—and urged the company to abandon its Alzheimer’s drug research. …

Alzheimer’s drug that can slow disease gets backing from FDA advisers
6 months, 2 weeks ago

Alzheimer’s drug that can slow disease gets backing from FDA advisers

Associated Press  

WASHINGTON — A closely watched Alzheimer’s drug from Eli Lilly won the backing of federal health advisers on Monday, setting the stage for the treatment’s expected approval for people with mild dementia caused by the brain-robbing disease. Food and Drug Administration advisers voted unanimously that the drug’s ability to slow the disease outweighs its risks, including side effects like brain …

FDA advisers strongly back new Alzheimer’s drug, despite risks and limitations
6 months, 2 weeks ago

FDA advisers strongly back new Alzheimer’s drug, despite risks and limitations

NPR  

FDA advisers strongly back new Alzheimer’s drug, despite risks and limitations toggle caption Andrew Harnik/AP Advisers to the Food and Drug Administration have recommended unanimously that the agency approve the Alzheimer’s drug donanemab. At a meeting Monday, the Peripheral and Central Nervous System Drugs Advisory Committee voted 11-0 that donanemab is effective at slowing down Alzheimer’s in the disease’s early …

It’s the first drug shown to slow Alzheimer’s. Why is it off to a slow start?
8 months, 1 week ago

It’s the first drug shown to slow Alzheimer’s. Why is it off to a slow start?

Associated Press  

The first drug shown to slow Alzheimer’s disease hit the U.S. market over a year ago, but sales have lagged, major hospital systems have taken months to start using it and some insurers have rejected coverage. “As we learn more, we’ll expand and extend it.” The Mayo Clinic in Rochester, Minnesota, started using Leqembi in October but only for patients …

FDA will take a deeper look into the safety and effectiveness of Lilly experimental Alzheimer’s drug
9 months, 2 weeks ago

FDA will take a deeper look into the safety and effectiveness of Lilly experimental Alzheimer’s drug

Associated Press  

INDIANAPOLIS — Federal regulators put off a decision on whether to approve an Eli Lilly Alzheimer’s drug by making an unusual request to have outside advisers look at the treatment. Eli Lilly and Co. Executive Vice President Anne White said in a statement that the Indianapolis-based company remains confident in donanemab’s potential and will work with the FDA. Donanemab is …

Biogen will stop selling its controversial Alzheimer’s drug Aduhelm
10 months, 3 weeks ago

Biogen will stop selling its controversial Alzheimer’s drug Aduhelm

Associated Press  

Biogen will stop selling its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster that stumbled after its launch a few years ago. The company also is helping Japanese drugmaker Eisai sell another Alzheimer’s treatment, Leqembi, which received full FDA approval last summer. When Aduhelm debuted in 2021, it was the first new Alzheimer’s drug in nearly two …

Insurers won’t cover new Alzheimer’s treatment for some customers
1 year, 4 months ago

Insurers won’t cover new Alzheimer’s treatment for some customers

Associated Press  

Some private insurers are balking at paying for the first drug fully approved to slow mental decline in Alzheimer’s patients. Insurers selling coverage in North Carolina, Pennsylvania and New York, among other states, told The Associated Press they won’t cover Leqembi with insurance offered on the individual market and through employers because they still see the $26,000-a-year drug as experimental. …

Why is this Alzheimer’s breakthrough so important?
1 year, 5 months ago

Why is this Alzheimer’s breakthrough so important?

The Independent  

Sign up for our free Health Check email to receive exclusive analysis on the week in health Get our free Health Check email Please enter a valid email address Please enter a valid email address SIGN UP I would like to be emailed about offers, events and updates from The Independent. Scientists found that donanemab was able to slow clinical …

New Alzheimer’s wonder drug ‘can slow disease progression by 60pc’
1 year, 5 months ago

New Alzheimer’s wonder drug ‘can slow disease progression by 60pc’

The Telegraph  

The NHS has just 88 positron emission tomography scanners which can detect amyloid plaques in the brain, one of the lowest per capita in the developed world. Hilary Evans, the chief executive of Alzheimer’s Research UK said: “Probably only two per cent of the people who could benefit from these drugs would necessarily get them because of those hurdles in …

New drug for Alzheimer's gives hope and ushers in new era in fighting the disease, says doctor
1 year, 5 months ago

New drug for Alzheimer's gives hope and ushers in new era in fighting the disease, says doctor

NL Times  

Alzheimer's used to be a disease that could not be cured. On Monday, however, the results of the second new drug for Alzheimer's will be announced, and that seems to herald a new era, says neurologist Niels Prins, director of the Brain Research Center. "It will be possible to counteract the disease, and that has never been done before in …

Alzheimer’s drug trials target older Californians. Do they understand what they’re signing up for?
1 year, 5 months ago

Alzheimer’s drug trials target older Californians. Do they understand what they’re signing up for?

LA Times  

For those fearing their memories are fading, the ads provide hope. In some cases, he has found, “they overpromise the likely results of these trials and create false hope.” Trinh is an executive at privately held Irvine Clinical Research, which says it “is the leading independent site” for Alzheimer’s drug trials in California. Tarsis Lopez, an Eli Lilly spokesperson, said …

US FDA grants standard approval of Eisai, Biogen Alzheimer's drug
1 year, 5 months ago

US FDA grants standard approval of Eisai, Biogen Alzheimer's drug

India Today  

Eisai and Biogen's Leqembi won a coveted standard approval nod from the U.S. Food and Drug Administration on Thursday, the first Alzheimer's treatment to achieve that goal, clearing the way for wider insurance coverage of the drug. The FDA placed its strongest "boxed" safety warning on Leqembi's label, flagging the risk of potentially dangerous brain swelling for Alzheimer's drugs in …

Alzheimer: This Country Has Approved New Drug That Will Combat Cognitive Decline
1 year, 5 months ago

Alzheimer: This Country Has Approved New Drug That Will Combat Cognitive Decline

News 18  

The US drug regulator gave full approval to a new Alzheimer’s medicine on Thursday, a move that makes it more widely available to the public through government-run health insurance for the elderly. “This confirmatory study verified that it is a safe and effective treatment for patients with Alzheimer’s disease,” senior FDA official Teresa Buracchio said in a statement. “This treatment, …

Alzheimer’s drug Leqembi has full FDA approval now and that means Medicare will pay for it
1 year, 5 months ago

Alzheimer’s drug Leqembi has full FDA approval now and that means Medicare will pay for it

Associated Press  

WASHINGTON — U.S. officials granted full approval to a closely watched Alzheimer’s drug on Thursday, clearing the way for Medicare and other insurance plans to begin covering the treatment for people with the brain-robbing disease. The Food and Drug Administration endorsed the IV drug, Leqembi, for patients with mild dementia and other symptoms caused by early Alzheimer’s disease. “This confirmatory …

Alzheimer's drug Leqembi gets full FDA approval. Medicare coverage will likely follow
1 year, 5 months ago

Alzheimer's drug Leqembi gets full FDA approval. Medicare coverage will likely follow

NPR  

Alzheimer's drug Leqembi gets full FDA approval. Medicare coverage will likely follow Enlarge this image toggle caption Andrew Harnik/AP Andrew Harnik/AP The Food and Drug Administration has fully approved the first drug shown to slow down Alzheimer's disease. In January, the drug received what's known as accelerated approval from the FDA, based on its ability to remove the substance beta-amyloid …

Alzheimer’s drug Leqembi has full FDA approval now and that means Medicare will pay for it
1 year, 5 months ago

Alzheimer’s drug Leqembi has full FDA approval now and that means Medicare will pay for it

LA Times  

This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. On Thursday, U.S. officials granted full approval to the closely watched Alzheimer’s drug, clearing the way for Medicare and other insurance plans to begin covering the treatment for people with the brain-robbing disease. U.S. officials granted full approval to a closely watched Alzheimer’s drug …

Opinion: New Alzheimer’s drugs are costly and controversial. Are we going about this all wrong?
1 year, 6 months ago

Opinion: New Alzheimer’s drugs are costly and controversial. Are we going about this all wrong?

LA Times  

An illustration depicting neurons in a brain affected by Alzheimer’s disease, with abnormal accumulations of beta-amyloid and tau proteins shown in brown and blue, respectively. The Food and Drug Administration’s recent approval of new Alzheimer’s drugs sparked a flicker of hope for the millions affected by this devastating disease. Eli Lilly’s stock price jumped 6.7% after it announced positive results …

Alzheimer's drug gets FDA panel's backing, setting the stage for broader use
1 year, 6 months ago

Alzheimer's drug gets FDA panel's backing, setting the stage for broader use

The Hindu  

Health advisers on Friday unanimously backed the full approval of a closely watched Alzheimer’s drug, a key step toward opening insurance coverage to U.S. seniors with early stages of the brain-robbing disease. The FDA panel of outside advisers voted 6-0 that a large company study confirmed the drug's benefits for patients with mild or early Alzheimer's. The FDA’s initial OK …

Alzheimer’s drug gets FDA panel’s backing, setting the stage for broader use
1 year, 6 months ago

Alzheimer’s drug gets FDA panel’s backing, setting the stage for broader use

Associated Press  

WASHINGTON — Health advisers on Friday unanimously backed the full approval of a closely watched Alzheimer’s drug, a key step toward opening insurance coverage to U.S. seniors with early stages of the brain-robbing disease. The FDA panel of outside advisers voted 6-0 that a large company study confirmed the drug’s benefits for patients with mild or early Alzheimer’s. The FDA’s …

Breakthrough Alzheimer’s drugs could be blocked by NHS, campaigners warn
1 year, 6 months ago

Breakthrough Alzheimer’s drugs could be blocked by NHS, campaigners warn

The Telegraph  

The first drugs to slow dementia could be denied to NHS patients because of rationing, campaigners and health experts have warned. Recent weeks have seen breakthroughs in Alzheimer’s research, sparking hopes of “the beginning of the end” of the disease, but the UK’s leading dementia charity fears the drugs will be blocked by NHS rationing bodies. Alzheimer’s Research UK has …

First ever drug found to slow Alzheimer’s submitted for approval
1 year, 6 months ago

First ever drug found to slow Alzheimer’s submitted for approval

The Telegraph  

The first ever drug found to slow Alzheimer’s has gone to Britain’s regulators for approval. The findings of the phase-three clinical trial were the first to ever show a drug can slow Alzheimer’s. Richard Oakley, Associate Director of Research at Alzheimer’s Society, said: “This is exciting progress and means that we could hear if lecanemab has been approved by early …

Benefits of lecanemab, a new Alzheimer's drug, unclear for patients of color : Short Wave : NPR
1 year, 9 months ago

Benefits of lecanemab, a new Alzheimer's drug, unclear for patients of color : Short Wave : NPR

NPR  

How well does a new Alzheimer's drug work for those most at risk? A new drug for Alzheimer's disease, called lecanemab, got a lot of attention earlier this year for getting fast-tracked approval based on a clinical trial that included nearly 1,800 people. The clinical trial for lecanemab was the most diverse for an Alzheimer's treatment to date, but it …

Why a new Alzheimer’s drug is having a slow US debut
1 year, 10 months ago

Why a new Alzheimer’s drug is having a slow US debut

Associated Press  

The first drug to show that it slows Alzheimer’s is on sale, but treatment for most patients is still several months away. Eisai spokeswoman Libby Holman said prescriptions for the drug have been written, and they expect patients to start receiving it “very soon.” COST AND COVERAGE A year’s treatment will run about $26,500. The Centers for Medicare and Medicaid …

EXPLAINER: New drug slows Alzheimer’s but comes with caveats
1 year, 11 months ago

EXPLAINER: New drug slows Alzheimer’s but comes with caveats

Associated Press  

WASHINGTON — A new Alzheimer’s drug is hitting the market — the first with clear-cut evidence that it can slow, by several months, the mind-robbing disease. In Eisai’s 18-month study of nearly 1,800 people, Leqembi appeared to delay early-stage patients from getting worse by about five months. People who got the drug still worsened but not as rapidly as those …

US: FDA approves anti-Alzheimer's drug
1 year, 11 months ago

US: FDA approves anti-Alzheimer's drug

Hindustan Times  

The US Food and Drug Administration on Friday approved a new drug designed to slow cognitive decline in those suffering from Alzheimer's disease. It follows the approval of the anti-Alzheimer's drug Aduhelm, which a US congressional investigation criticized for alleged "irregularities." The FDA said in a statement that Leqembi and Aduhelm represent "an important advancement in the ongoing fight to …

US approves Alzheimer’s drug that modestly slows disease
1 year, 11 months ago

US approves Alzheimer’s drug that modestly slows disease

Associated Press  

WASHINGTON — U.S. health officials on Friday approved a closely watched Alzheimer’s drug that’s been shown to modestly slow the early stages of the brain-robbing disease, albeit with potential safety risks that doctors and patients will have to carefully weigh. Last week, a congressional report found that FDA’s approval of a similar Alzheimer’s drug called Aduhelm — also from Biogen …

U.S. approves Alzheimer’s drug that modestly slows disease
1 year, 11 months ago

U.S. approves Alzheimer’s drug that modestly slows disease

LA Times  

This Dec. 21, 2022 image provided by Eisai in January 2023, shows vials and packaging for their medication Leqembi. U.S. health officials on Friday approved a closely watched Alzheimer’s drug that modestly slows the brain-robbing disease, albeit with potential safety risks that patients and their doctors will have to carefully weigh. Last week, a congressional report found that FDA’s approval …

Probe: Alzheimer’s drug approval ‘rife with irregularities’
1 year, 11 months ago

Probe: Alzheimer’s drug approval ‘rife with irregularities’

Associated Press  

WASHINGTON — The Food and Drug Administration’s contentious approval of a questionable Alzheimer’s drug took another hit Thursday as congressional investigators called the process “rife with irregularities.” The 18-month investigation by two House committees detailed “atypical collaboration” between FDA regulators and a company it’s supposed to oversee -- Aduhelm manufacturer Biogen. Thursday’s report urged the agency to “take swift action” …

Alzheimer’s drug approval by FDA ‘rife with irregularities,’ probe finds
1 year, 11 months ago

Alzheimer’s drug approval by FDA ‘rife with irregularities,’ probe finds

LA Times  

The FDA’s contentious approval of the questionable Alzheimer’s drug Aduhelm took another hit, as congressional investigators called the process “rife with irregularities.” The Food and Drug Administration’s contentious approval of a questionable Alzheimer’s drug took another hit Thursday as congressional investigators called the process “rife with irregularities.” The 18-month investigation by two House committees detailed “atypical collaboration” between FDA regulators …

Alzheimer's drug from Eisai and Biogen slows cognitive decline, side-effects in focus
2 years ago

Alzheimer's drug from Eisai and Biogen slows cognitive decline, side-effects in focus

The Hindu  

An experimental Alzheimer's disease drug from Eisai and Biogen slowed cognitive decline in a closely watched trial but may carry a risk of dangerous side effects for certain patients, according to new data presented on Tuesday. The companies said in September that the 18-month trial, which enrolled nearly 1,800 participants with early-stage Alzheimer's, found that treatment with lecanemab reduced the …

Breakthrough: A drug slows Alzheimer’s by 5 months, but will it make a big difference?
2 years ago

Breakthrough: A drug slows Alzheimer’s by 5 months, but will it make a big difference?

Firstpost  

On Tuesday, Japanese drugmaker Eisai and its US partner Biogen reported that an experimental Alzheimer’s drug had modestly slowed the brain disease’s inevitable worsening. However, it is unclear how much of a difference this would make in people’s lives An experimental Alzheimer’s drug modestly slowed the brain disease’s inevitable worsening, researchers reported Tuesday — but it remains unclear how much …

New drug appears to slow Alzheimer’s, but can it make a real difference?
2 years ago

New drug appears to slow Alzheimer’s, but can it make a real difference?

LA Times  

An experimental Alzheimer’s drug modestly slowed the brain disease’s inevitable worsening, researchers reported Tuesday — but it remains unclear how much difference that might make in people’s lives. Japanese drugmaker Eisai and its U.S. partner, Biogen, had announced earlier this fall that the drug, lecanemab, appeared to work, a badly needed bright spot after repeated disappointments in the quest for …

Drug that reverses dementia will be wasted without better diagnosis rates, experts warn
2 years ago

Drug that reverses dementia will be wasted without better diagnosis rates, experts warn

The Telegraph  

The latest published data shows that as of 2019, Britain had just 70 PET-CT scanning locations, less than half the number of those available in comparable EU countries. “We need everyone to be told which disease is causing their dementia symptoms, and if they have Alzheimer’s disease, a follow-up scan or CSF test to check if they are amyloid positive …

Alzheimer’s drug shows promise in early results of study
2 years, 2 months ago

Alzheimer’s drug shows promise in early results of study

Associated Press  

Shares of Biogen and other drugmakers researching Alzheimer’s disease soared Wednesday after Japan’s Eisai Co. said its potential treatment appeared to slow the fatal disease in a late-stage study. The drugmaker said early results showed that its treatment, lecanemab, reduced patient clinical decline by 27% when compared to a placebo or fake drug after 18 months of the infused treatment. …

Change at the top for Biogen after Alzheimer’s drug flops
2 years, 7 months ago

Change at the top for Biogen after Alzheimer’s drug flops

Associated Press  

Biogen will replace its CEO and largely abandon marketing of its controversial Alzheimer’s drug Aduhelm less than a year after the medication’s launch triggered a backlash from experts, doctors and insurers. For now, Biogen said it is “substantially eliminating” spending on Aduhelm as part of a $1 billion dollar cost-saving plan designed to refocus the company’s flagging biotech business. Aduhelm …

Medicare limits coverage of $28,000-a-year Alzheimer’s drug
2 years, 11 months ago

Medicare limits coverage of $28,000-a-year Alzheimer’s drug

Associated Press  

WASHINGTON — Medicare said Tuesday it will limit coverage of a $28,000-a-year Alzheimer’s drug whose benefits have been widely questioned, a major development in the nation’s tug-of-war over the fair value of new medicines that offer tantalizing possibilities but come with prohibitive prices. “CMS has been and remains committed to providing the American public with a clear, trusted, evidence-based decision …

Medicare limits coverage of $28,000-a-year Alzheimer’s drug
2 years, 11 months ago

Medicare limits coverage of $28,000-a-year Alzheimer’s drug

LA Times  

Medicare said Tuesday it will limit coverage of a $28,000-a-year Alzheimer’s drug whose benefits have been widely questioned, a major development in the nation’s tug-of-war over the fair value of new medicines that offer tantalizing possibilities but come with prohibitive prices. “Alzheimer’s disease is a devastating illness that has touched the lives of millions of American families,” Medicare administrator Chiquita …

Alzheimer’s drug cited as Medicare premium jumps by $21.60
3 years, 1 month ago

Alzheimer’s drug cited as Medicare premium jumps by $21.60

Associated Press  

WASHINGTON — Medicare’s “Part B” outpatient premium will jump by $21.60 a month in 2022, one of the largest increases ever. Medicare officials told reporters on Friday that about half the increase is due to contingency planning if the program ultimately has to cover Aduhelm, the new $56,000-a-year medication for Alzheimer’s disease from pharmaceutical company Biogen. “The increase in the …

In quiet debut, Alzheimer’s drug finds questions, skepticism
3 years, 2 months ago

In quiet debut, Alzheimer’s drug finds questions, skepticism

Associated Press  

The first new Alzheimer’s treatment in more than 20 years was hailed as a breakthrough when regulators approved it more than four months ago, but its rollout has been slowed by questions about its price and how well it works. “It’s like a breath of fresh air,” said Dr. Stephen Salloway, a Rhode Island neurologist and Biogen consultant who is …

New Alzheimer's drug aducanumab is dividing doctors and patients, as the TGA weighs up its risk-benefit profile
3 years, 4 months ago

New Alzheimer's drug aducanumab is dividing doctors and patients, as the TGA weighs up its risk-benefit profile

ABC  

After a decades-long career as a biology teacher, John Rodgers applies the strict logic of a scientist to answer tough questions. Key points: Patients have mixed views about the first new Alzheimer's drug in two decades The TGA is deciding whether it's safe and a second committee will decide whether the government will pay to make it available Australian experts …

Ad campaign for controversial Alzheimer’s drug will ‘overly medicalize’ normal age-related memory loss, some experts say
3 years, 5 months ago

Ad campaign for controversial Alzheimer’s drug will ‘overly medicalize’ normal age-related memory loss, some experts say

CNN  

CNN — Do you sometimes lose your train of thought or feel a bit more anxious than is typical for you? The campaign — which also includes a detailed “It’s particularly egregious because they are trying to convince people with either normal memories or normal age-related decline that they are ill and they need a drug,” said Dr. Adriane Fugh-Berman, …

Discover Related